p-(N-morpholino)aniline hydrochloride | 200711-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: p-(N-morpholino)aniline hydrochloride
• 英文别名: 4-morpholinobenzenaminium chloride；4-Morpholinoanilinehydrochloride；4-morpholin-4-ylaniline;hydrochloride
• CAS: 200711-87-1
• 化学式: C₁₀H₁₄N₂O*ClH
• 分子量: 214.695
• InChiKey: QHIYRZFZKWLHSS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.53
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-(4-硝基苯基)吗啉 在 二乙基硅烷 、 四(3,5-二(三氟甲基)苯基)硼酸钠 、 Co(dppbsa) 、 盐酸 作用下， 以 甲苯 、 乙醚 为溶剂， 以81 %的产率得到p-(N-morpholino)aniline hydrochloride
  参考文献：
  名称：

  Co(dppbsa)-catalyzed reductive N,N-dimethylation of nitroaromatics with CO₂ and hydrosilane

  摘要：

  合成了一种新型半夹心 Co（dppbsa）（[Co]），并用于催化硝基芳烃与二氧化碳和氢硅烷的 N,N-二甲基化反应。该催化剂还能高效地将硝基芳烃还原成芳香胺。

  DOI：

  10.1039/d3gc02517a

文献信息

• Hydrogenation of Aromatic Nitro Compounds with an Inexpensive and Efficient CuSO₄/CoCl₂Catalyst Prepared<i>in situ</i>using NaBH₄as the Hydrogen Source
  作者：Mario Ficker、Johannes F. Petersen、Jon S. Hansen、Jørn B. Christensen

  DOI：10.1080/00304948.2014.884374

  日期：2014.3.4
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：Courtney Stephen Martin

  公开号：US20140329795A1

  公开（公告）日：2014-11-06

  Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
• US9428464B2
  申请人：——

  公开号：US9428464B2

  公开（公告）日：2016-08-30